Pacific Edge has reported that test volumes processed in their laboratories in the three months to the end of December 2022 increased 36% compared to the same three-month period in the previous year.
This growth rate is in line with the year-on-year growth rates achieved in previous quarters, although the company noted a traditional slowdown from Thanksgiving to the New Year.
Pacific Edge is a cancer diagnostics company providing non-invasive genomic urine tests for the detection and management of bladder cancer.
See more
